The Global Asthma
Therapeutics Market, by Drug Class
(Corticosteroids, Beta2-Agonists (Long-acting and Short-acting), Leukotriene Inhibitors,
Long-acting Muscarinic Antagonists (LAMA), Interleukin Antagonists,
Anti-immunoglobulin E (IgE) Agents, Combination Products (Including Beta2
Agonists/Corticosteroids, Beta2 Agonists/Muscarinic
Antagonists/Corticosteroids, and Others), and Others), by Route of
Administration (Oral, Inhalation, and Injection), by Distribution Channel
(Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region
(North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),
was valued at US$ XX million in 2017, and is projected to exhibit a CAGR of
1.9%, during the forecast period (2018 - 2026), as highlighted in a new report
published by Coherent Market Insights.
Inhaler is a medical device,
which facilitates the delivery of drug into body through lungs. It is mainly
used in the treatment of respiratory diseases and disorders including asthma
and chronic obstructive pulmonary disease (COPD). Inhaler divided into two
types such as metered-dose inhaler and dry powder inhaler. Metered-dose
inhalers are also called as aerosol-based inhalers. Dry powder inhalers are an
alternative of metered-dose-inhalers.
Thus, increasing approval for
inhalers by regulatory authorities is expected to drive the global asthma
therapeutics market growth. For instance, in January 2019, Teva Pharmaceuticals
Industries received U.S. Food and Drug Administration (USFDA) approval for its
new (ProAir Digihaler) digital Inhaler. It is used for the improvement and
treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). ProAir
Digihaler is a first digital inhaler. It is multi-dose dry powder inhaler, which
delivers 117 µg of Albuterol.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2698
Furthermore, increasing number of
clinical trials for treatment of asthma is expected to boost the global asthma
therapeutics market value. For instance, in May 2018, Montefiore Medical Center
initiated clinical study to evaluate the performance of ‘Adapting and Expanding
the Algorithmic Software Tool (ASTHMAXcel App)’. This software teaches
fundamental concept of asthma and its management. The study started in May
2018, and it is expected to complete in April 2020.
Browse 23 Market Data Tables and
19 Figures spread through 157 Pages and in-depth TOC on "Asthma
Therapeutics Market, by Drug Class
(Corticosteroids, Beta2-Agonists (Long-Acting and Short-Acting), Leukotriene
Inhibitors, Long-Acting Muscarinic Antagonists (LAMA), Interleukin Antagonists,
Anti-Immunoglobulin E (IgE) Agents, Combination Products (Including Beta2
Agonists/Corticosteroids, Beta2 Agonists/Muscarinic
Antagonists/Corticosteroids, and Others), and Others), by Route of
Administration (Oral, Inhalation, and Injection), and by Distribution Channel
(Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies), and by Region
(North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -
Global Forecast to 2026"
Key players in the market are
focused on launching new products for asthma treatment. For instance, in May
2019, FindAir Company, launched its new Smart Inhaler Device FindAir One in
Europe. It is used for treatment of asthma and chronic obstructive pulmonary
disease (COPD). Moreover, in January 2019, FindAir One received CE marking for
distribution in the Europe.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/asthma-therapeutics-market-2698
Moreover, consistent research and
development activities are expected to drive the global asthma therapeutics
market growth. For instance, in March 2018, Interregional Public Organization
and Russian Respiratory Society initiated a clinical study to collect anonymous
long-term evidences of severe asthma patients in Russia. The study is expected
to complete in December 2022. Furthermore, in February 2019, University of
Chicago initiated phase II clinical study on Azithromycin for treatment of
asthma. This study is expected to complete in February 2020.
Key Takeaways of the Global
Asthma Therapeutics Market:
The global asthma therapeutics
market is expected to witness a CAGR of 1.9% during the forecast period
(2018–2026), owing to increasing product launches for improvement of
respiratory disease including asthma and chronic obstructive pulmonary disease
(COPD)
Among the regions, North America
is expected hold largest market share in global asthma therapeutics market over
the forecast period, owing to rising prevalence of respiratory diseases in the
U.S. For instance, according to Centers for Disease Control and Prevention
(CDC), in 2016, around 24 million people, including over 6 million children,
suffered from asthma in the U.S.
Major players operating in the
global asthma therapeutics market GlaxoSmithKline Plc., Philips Healthcare,
AstraZeneca, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH,
Sanofi-Aventis SA, CareFusion Corporation, Sunovion Pharmaceuticals, Inc. Merck
& Co., Inc., and Roche Diagnostics
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2698
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment